المؤلفون: Angela Meade, Elena Frangou, Babak Choodari-Oskooei, James Larkin, Tom Powles, Grant D. Stewart, Laurence Albiges, Axel Bex, Toni K. Choueiri, Ian D. Davis, Tim Eisen, Alison Fielding, Craig Gedye, David J. Harrison, Rick Kaplan, Salena Mulhere, Paul Nathan, Grisma Patel, Jay Patel, Hannah Plant, Alastair Ritchie, Hannah Rush, Clare Shakeshaft, Martin R. Stockler, Cristina Suarez, Jemima Thompson, Nat Thorogood, Balaji Venugopal, Mahesh K.B. Parmar

المصدر: Contemporary Clinical Trials Communications, Vol 42, Iss , Pp 101381- (2024)

مصطلحات موضوعية: Medicine (General), R5-920

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2451865424001285; https://doaj.org/toc/2451-8654

URL الوصول: https://doaj.org/article/152a532dd63f4c618fd32817ead311e1

المؤلفون: Laurence Albiges, Martin R. Stockler, Grant D. Stewart, Alastair W. S. Ritchie, Sarah Scovell, Tim Eisen, Salena Mulhere, Mahesh K. B. Parmar, Ben Smith, Brian I. Rini, David J. Harrison, Richard Kaplan, Thomas Powles, Nat Thorogood, Hanna Bryant, Anita McWhirter, Bhavna Oza, Alison Fielding, James Larkin, Angela M. Meade, Axel Bex, Ian D. Davis, Clare Shakeshaft, Babak Choodari-Oskooei, Paul Nathan, Eleni Frangou, Toni K. Choueiri

المساهمون: University of St Andrews. School of Medicine, University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Cellular Medicine Division

المصدر: Contemporary Clinical Trials

مصطلحات موضوعية: Oncology, medicine.medical_specialty, RM, Durvalumab, Combination therapy, medicine.medical_treatment, Placebo, Article, RC0254, SDG 3 - Good Health and Well-being, Recurrence, Renal cell carcinoma, Internal medicine, RAMPART, medicine, Humans, Pharmacology (medical), Platform trial, Carcinoma, Renal Cell, business.industry, RC0254 Neoplasms. Tumors. Oncology (including Cancer), General Medicine, 3rd-DAS, medicine.disease, Kidney Neoplasms, Nephrectomy, RM Therapeutics. Pharmacology, Radiation therapy, Check-point inhibitor, Renal cancer, Chronic Disease, MAMS, Quality of Life, business, Adjuvant, Tremelimumab, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b398c819f256a4095399e1c7d91222e7
https://hdl.handle.net/10023/23999

المؤلفون: Richard Kaplan, Hanna Bryant, Mahesh K. B. Parmar, Paul Nathan, Martin R. Stockler, Ian D. Davis, James Larkin, David J. Harrison, Salena Mulhere, Bhavna Oza, Alison Fielding, Babak Choodari-Oskooei, Grant D. Stewart, Tim Eisen, Sarah Scovell, Nat Thorogood, Toni K. Choueiri, Anita McWhirter, Laurence Albiges, Brian I. Rini, Thomas Powles, Ben Smith, Eleni Frangou, Clare Shakeshaft, Alastair W. S. Ritchie, Axel Bex, Angela M. Meade

المساهمون: University of St Andrews. School of Medicine, University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Cellular Medicine Division

المصدر: Contemporary clinical trials. 108

مصطلحات موضوعية: medicine.medical_specialty, RM, Locally advanced, Phase (combat), RC0254, SDG 3 - Good Health and Well-being, RAMPART, London, Medicine, Humans, Pharmacology (medical), Medical physics, Platform trial, Trial registration, License, Carcinoma, Renal Cell, Protocol (science), business.industry, RC0254 Neoplasms. Tumors. Oncology (including Cancer), General Medicine, Regulatory Submission, Kidney Neoplasms, RM Therapeutics. Pharmacology, Clinical trial, Renal cancer, MAMS, T-DAS, Durvalumab, business, Tremelimumab

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0194c3ee0d4a13bc0ec0088f3a6189b2
https://pubmed.ncbi.nlm.nih.gov/34538401